Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement stakeholders criticize folic acid-cancer study

This article was originally published in The Tan Sheet

Executive Summary

A report analyzing the association of folic acid and vitamin B12 supplementation with increased cancer incidence contains numerous flaws, says the Council for Responsible Nutrition and the Natural Products Association. The Journal of the American Medical Association published the 1study Nov. 18, which looked at two Norwegian homocysteine-lowering trials of patients with ischemic heart disease. Researchers led by Marta Ebbing of Haukeland University in Bergen, Norway, found in the combined analysis of 6,837 patients that the study population had a 25 percent higher incidence of lung cancer than the general population of Norway, where there is no folic acid fortification. NPA's VP of Scientific and Regulatory Affairs Daniel Fabricant called the study "flawed" due to its lack of analysis into intervening factors, including patients' treatment with beta-blockers and statins. Andrew Shao, VP of scientific and regulatory affairs for CRN, said the conclusions are "inconsistent with the larger body of data" on folic acid's benefits and with the inverse relationship between folic acid fortification and lung cancer incidence in the U.S

You may also be interested in...



Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.

Topics

UsernamePublicRestriction

Register

PS103582

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel